P D Delmas

Summary

Country: France

Publications

  1. ncbi request reprint Treatment of postmenopausal osteoporosis
    Pierre D Delmas
    Claude Bernard University of Lyon and INSERM Research Unit 403, France
    Lancet 359:2018-26. 2002
  2. ncbi request reprint Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial
    Pierre D Delmas
    University of Claude Bernard of Lyon, Hopital Edouard Herriot, Service de Rhumatologie et de Pathologie Osseuse, Lyon 69437, France
    J Clin Endocrinol Metab 87:3609-17. 2002
  3. ncbi request reprint The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis
    P D Delmas
    INSERM Research Unit 403 and Claude Bernard University of Lyon, France
    Osteoporos Int 13:1-5. 2002
  4. ncbi request reprint Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis
    P D Delmas
    INSERM Research Unit 403 and Claude Bernard University of Lyon, Lyon, France
    Bone 30:14-7. 2002
  5. ncbi request reprint Monitoring individual response to hormone replacement therapy with bone markers
    P D Delmas
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 26:553-60. 2000
  6. ncbi request reprint Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study
    P Chavassieux
    , , Lyon, France
    J Bone Miner Res 16:89-96. 2001
  7. pmc Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage
    P Garnero
    INSERM Research Unit 403, Lyon, France
    Ann Rheum Dis 60:619-26. 2001
  8. ncbi request reprint Cross-sectional evaluation of bone metabolism in men
    P Szulc
    INSERM Research Unit 403, Lyon, France
    J Bone Miner Res 16:1642-50. 2001
  9. ncbi request reprint Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women
    P Garnero
    INSERM U 403, Hopital E Herriot, Lyon, France
    J Clin Endocrinol Metab 84:2390-7. 1999
  10. ncbi request reprint Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Osteoporos Int 8:563-9. 1998

Detail Information

Publications131 found, 100 shown here

  1. ncbi request reprint Treatment of postmenopausal osteoporosis
    Pierre D Delmas
    Claude Bernard University of Lyon and INSERM Research Unit 403, France
    Lancet 359:2018-26. 2002
    ..Non-pharmacological interventions include adequate calcium intake and diet, selected exercise programmes, reduction of other risk factors for osteoporotic fractures, and reduction of the risk of falls in elderly individuals...
  2. ncbi request reprint Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial
    Pierre D Delmas
    University of Claude Bernard of Lyon, Hopital Edouard Herriot, Service de Rhumatologie et de Pathologie Osseuse, Lyon 69437, France
    J Clin Endocrinol Metab 87:3609-17. 2002
    ..The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr...
  3. ncbi request reprint The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis
    P D Delmas
    INSERM Research Unit 403 and Claude Bernard University of Lyon, France
    Osteoporos Int 13:1-5. 2002
    ..A relative margin of non-inferiority of 20-30% is suggested, to be discussed on a case by case basis...
  4. ncbi request reprint Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis
    P D Delmas
    INSERM Research Unit 403 and Claude Bernard University of Lyon, Lyon, France
    Bone 30:14-7. 2002
    ..These discrepancies stress the differences in the pathogenesis of vertebral and nonvertebral fractures as discussed below, and the need to further investigate the mechanisms of action of various antiresorptive agents...
  5. ncbi request reprint Monitoring individual response to hormone replacement therapy with bone markers
    P D Delmas
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 26:553-60. 2000
    ..Our data suggest that bone turnover markers can be used to monitor the BMD response to HRT at the individual level. Whether such monitoring could improve long-term compliance to HRT should be tested prospectively...
  6. ncbi request reprint Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study
    P Chavassieux
    , , Lyon, France
    J Bone Miner Res 16:89-96. 2001
    ..These effects on cortical bone were reflected by changes in biochemical markers. MDL markedly reduces bone turnover and increases BMD suggesting that this new agent may prevent postmenopausal bone loss...
  7. pmc Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage
    P Garnero
    INSERM Research Unit 403, Lyon, France
    Ann Rheum Dis 60:619-26. 2001
    ..The clinical performance of these two new markers was compared with that of a panel of other established biochemical markers of connective tissue metabolism...
  8. ncbi request reprint Cross-sectional evaluation of bone metabolism in men
    P Szulc
    INSERM Research Unit 403, Lyon, France
    J Bone Miner Res 16:1642-50. 2001
    ..After the age of 60 years, bone resorption markers--but not bone formation markers--increase in some men and are associated with lower BMD, suggesting that this imbalance is responsible for increasing bone loss in elderly men...
  9. ncbi request reprint Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women
    P Garnero
    INSERM U 403, Hopital E Herriot, Lyon, France
    J Clin Endocrinol Metab 84:2390-7. 1999
    ..The delayed decrease in bone formation observed with intranasal E2 compared to oral E2 may be related to different effects on serum IGF-I levels...
  10. ncbi request reprint Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Osteoporos Int 8:563-9. 1998
    ..If DXA is not available, the combination of history of fracture and urinary CTX performs as well as hip BMD to assess hip fracture risk in elderly women...
  11. ncbi request reprint Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
    P D Delmas
    INSERM Research Unit 403, Claude Bernard University of Lyon, Lyon, France
    Bone 39:237-43. 2006
    ..Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk...
  12. ncbi request reprint The collagenolytic activity of cathepsin K is unique among mammalian proteinases
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Pav F, 69437 Lyon Cedex 03, France
    J Biol Chem 273:32347-52. 1998
    ..This property of cathepsin K is unique among mammalian proteinases and is reminiscent of bacterial collagenases. It is likely to be responsible for the key role of cathepsin K in bone resorption...
  13. ncbi request reprint Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products
    P Garnero
    INSERM Unit 403, Department of Immunology, Hopital Edouard Herriot, Lyon, France
    Bone 24:381-5. 1999
    ..Bone formation appears to be reduced both in patients with and without joint destruction, whereas resorption is increased only in patients with joint destruction in relation to disease activity...
  14. ncbi request reprint Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
    P D Delmas
    Inserm Unite 403, Physiopathologie, Hopital Edouard Herriot, 5 Place d Arsonval, Lyon Cedex 3, France
    Osteoporos Int 15:792-8. 2004
    ..Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis...
  15. doi request reprint Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women
    P D Delmas
    INSERM Research Unit 831 and University of Lyon, Lyon, France
    Osteoporos Int 19:1153-60. 2008
    ..Tibolone increased lumbar spine and total hip BMD to a statistically significantly greater extent than raloxifene after two years of treatment...
  16. doi request reprint Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone
    S Viguet-Carrin
    INSERM Research Unit 831 and Claude Bernard University of Lyon, Lyon, France
    Bone 46:342-7. 2010
    ....
  17. ncbi request reprint Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study
    P Garnero
    Synarc 16 rue Montbrillant 69003, Lyon, France
    Bone 40:716-22. 2007
    ..The aim of this study was to investigate the associations between serum 25-hydroxyvitamin D (25-OH D), bone turnover markers, bone mineral density (BMD), radius bone loss and incidence of fracture in postmenopausal women...
  18. doi request reprint Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study
    A Chaitou
    INSERM Research Unit 1033, Hopital Edouard Herriot, Universite de Lyon 1, Place d Arsonval, 69437 Lyon, France
    Eur J Endocrinol 165:151-9. 2011
    ..We assessed the association of bone microarchitecture with calcium intake and serum concentrations of 25-hydroxycholecalciferol (25OHD) and parathyroid hormone (PTH) in men...
  19. ncbi request reprint Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS study
    P Szulc
    INSERM Research Unit 403, Lyon, France
    Osteoporos Int 12:302-10. 2001
    ..Grade 1 deformities are often either false positive or deformities related to nonosteoporotic disease of the spine...
  20. ncbi request reprint The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Pav F, 69003 Lyon, France
    Bone 28:461-4. 2001
    ..Measurement of type II collagen breakdown by a new urinary biochemical marker may be useful for in vivo assessment of the effects of drugs that potentially inhibit cartilage destruction...
  21. ncbi request reprint Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis
    P Garnero
    INSERM Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    Clin Chem 47:694-702. 2001
    ..Our aim was to evaluate the technical and clinical performances of a new, fully automated assay for serum C-terminal cross-linking telopeptide of type I collagen (CTX), a marker of bone resorption...
  22. pmc Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study
    P Szulc
    INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69437, Lyon, France
    Osteoporos Int 18:495-503. 2007
    ..The aim of this study was to assess age-related apparent net and endosteal bone loss as well as their morphological basis and age-related changes during a prospective follow-up in a large cohort of elderly men...
  23. ncbi request reprint Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation
    E Gineyts
    INSERM Research Unit 403, , Lyon and. SYNARC, Lyon, France
    Rheumatology (Oxford) 40:315-23. 2001
    ..CONCLUSION: Glc-Gal-PYD may be useful for the clinical investigation of patients with joint disease...
  24. ncbi request reprint A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    Bone 24:603-9. 1999
    ..Because this model is independent of the study design, it should be broadly applicable...
  25. ncbi request reprint Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density
    P Garnero
    Institut National de la Santé et de la Recherche Médicale Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    J Clin Endocrinol Metab 90:4829-35. 2005
    ..Vitamin D receptor (VDR) gene polymorphisms explain only a small part of the genetic influence on the level of bone mineral density (BMD), whereas their effect on fracture remains uncertain...
  26. ncbi request reprint Role of sex steroids in the regulation of bone morphology in men. The MINOS study
    P Szulc
    INSERM Research Unit 403, Hopital Edouard Herriot, Place d Arsonval, 69437, Lyon, France
    Osteoporos Int 15:909-17. 2004
    ....
  27. ncbi request reprint Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
    C B Confavreux
    INSERM Research Unit 831 and University of Lyon, Rheumatology Department, Hopital Edouard Herriot, Lyon, France
    Bone 41:346-52. 2007
    ..The bisphosphonate risedronate prevents anastrozole induced bone loss...
  28. ncbi request reprint Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results
    P D Delmas
    University of Lyon and INSERM Research Unit 831, Lyon, France
    Osteoporos Int 19:1039-45. 2008
    ..Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule...
  29. doi request reprint Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis
    P Szulc
    INSERM Research Unit 831, Hopital Edouard Herriot, Lyon, France
    Osteoporos Int 19:1683-704. 2008
    ..The aim was to analyse data on the use of biochemical bone turnover markers (BTM) in postmenopausal osteoporosis...
  30. ncbi request reprint Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction
    P Clezardin
    INSERM U 234, , Lyon, France
    Cancer Res 51:2621-7. 1991
    ..6 x 10(6) cells/ml).(ABSTRACT TRUNCATED AT 400 WORDS)..
  31. pmc Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover
    E Gineyts
    INSERM U403, Hopital E Herriot, Pavillon F, Place d Arsonval, 69437 Lyon Cedex 03, France
    Biochem J 345:481-5. 2000
    ....
  32. doi request reprint In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization
    G Boivin
    INSERM Unité 831, Faculté de Médecine R Laennec, Universite de Lyon, Lyon, France
    Osteoporos Int 21:667-77. 2010
    ..Strontium was shown to be dose-dependently deposited into this newly formed bone with preservation of the mineralization...
  33. doi request reprint Risk factors for peripheral fractures vary by age in older men--the prospective MINOS study
    S Blaizot
    INSERM 831 Research Unit, Universite de Lyon, Lyon, France
    Osteoporos Int 22:1755-64. 2011
    ..Identification of older men at high risk of peripheral fracture can be improved by assessing prevalent fractures (men aged ≤ 65), history of falls (men aged >65), bone width, and aortic calcifications...
  34. ncbi request reprint Glutamate receptors are expressed by bone cells and are involved in bone resorption
    C Chenu
    INSERM, Unit 403, Hopital E Herriot, Lyon, France
    Bone 22:295-9. 1998
    ..These results suggest a possible new mechanism for regulating osteoclast activity and indicate that excitatory amino acids such as glutamate may be important local regulators of bone cell functions...
  35. ncbi request reprint Cross-sectional and longitudinal assessment of pre- and postmenopausal bone loss with a portable forearm X-ray device: the Ofely study
    F Duboeuf
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 26:131-5. 2000
    ....
  36. ncbi request reprint The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation
    P Garnero
    INSERM Unit 403, Hopital E Herriot, Lyon, France
    J Bone Miner Res 18:859-67. 2003
    ..We conclude that the generation of ICTP and CTX depends on different collagenolytic pathways. This finding may explain why these two markers may discriminate between different bone pathologies...
  37. ncbi request reprint The role of collagen in bone strength
    S Viguet-Carrin
    INSERM Research Unit 403 and Claude Bernard University, Lyon, France
    Osteoporos Int 17:319-36. 2006
    ..To illustrate the role of the crosslinking process of collagen in bone strength, clinical disorders associated with bone collagen abnormalities and bone fragility, such as osteogenesis imperfecta and osteoporosis, are described...
  38. ncbi request reprint High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study
    P Szulc
    INSERM Research Unit 831, Hopital Edouard Herriot, Pavillon F, 69437 Lyon, France
    Ann Rheum Dis 67:1249-55. 2008
    ..The morphological basis of such a relationship is unknown. The objective of this study was to evaluate the association between baseline BTM levels and subsequent bone loss and fracture risk in men...
  39. ncbi request reprint Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study
    P Szulc
    INSERM 403 Research Unit, Hopital Edouard Herriot, Pavillon F Place d Arsonval, 69437, Lyon, France
    Osteoporos Int 17:231-6. 2006
    ..Thus, the independent contribution of the external diameter of the femoral neck to the risk of hip fracture cannot be reliably estimated by this technique...
  40. ncbi request reprint Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study
    P Szulc
    Institut National de la Sante et de la Recherche Medicale, 403 Research Unit, Hopital Edouard Herriot, 69437 Lyon, France
    J Clin Endocrinol Metab 88:5240-7. 2003
    ....
  41. doi request reprint Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial
    R D Chapurlat
    Inserm U1033, Universite de Lyon, Hopital E Herriot, Lyon, France
    Osteoporos Int 24:311-20. 2013
    ....
  42. ncbi request reprint Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis
    J C Rousseau
    INSERM Unit 403, Pavillon F, Hopital E Herriot, Lyon, France
    Osteoarthritis Cartilage 12:440-7. 2004
    ..In addition, we investigated circulating forms recognized by antiserum IIA in pools of serum from healthy adults, patients with OA and patients with RA...
  43. ncbi request reprint Biochemical markers of bone formation reflect endosteal bone loss in elderly men--MINOS study
    P Szulc
    INSERM 403 Research Unit, Hopital Edouard Herriot, Claude Bernard University, Lyon, France
    Bone 36:13-21. 2005
    ..In contrast, they do not reflect the periosteal bone formation, probably because the periosteal surface is smaller and has a slower remodelling rate than the endosteal surface...
  44. pmc Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis
    E Gineyts
    INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69003 Lyon, France
    Ann Rheum Dis 63:857-61. 2004
    ....
  45. ncbi request reprint Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
    R D Chapurlat
    Department of Rheumatology and Bone Disease and INSERM Unit 403, Hopital E Herriot, 5 Place d Arsonval, 69437, Lyon, Cedex 03, France
    Osteoporos Int 17:1189-95. 2006
    ....
  46. ncbi request reprint Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae
    S Viguet-Carrin
    INSERM Research Unit 403 and Université Claude Bernard Lyon I, Lyon, France
    Bone 39:1073-9. 2006
    ..83, P = 0.015). These findings indicate that post-translational modifications of type I collagen have an impact on skeletal fragility...
  47. ncbi request reprint The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients
    G Boivin
    INSERM Unité 831, Universite de Lyon, Faculté de Médecine R Laennec, Lyon, France
    Bone 43:532-8. 2008
    ..Bone microhardness is linked to Young's modulus of bone and is strongly correlated to mineralization, but the organic matrix accounts for about one third of its variance...
  48. ncbi request reprint An in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties
    S Viguet-Carrin
    INSERM Research Unit 831 University of Lyon, Lyon, France
    Bone 42:139-49. 2008
    ..AGE concentration did not influence bending mechanical properties; however, the simple 3-point bending test we used was likely inadequate to demonstrate effects of AGEs on mechanical properties...
  49. doi request reprint FRAX® probabilities and risk of major osteoporotic fracture in France
    C M Couris
    Pôle IMER, Hospices Civils de Lyon, Lyon, France
    Osteoporos Int 23:2321-7. 2012
    ....
  50. ncbi request reprint An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis
    P Garnero
    INSERM Research Unit 403, Hôpital E Herriot Pavillon F, 69437 Lyon Cedex 03, France
    Bone 32:20-6. 2003
    ..The test was a sensitive indicator of the antiresorptive effects of bisphosphonate and estrogens in postmenopausal women. This new bone resorption marker should be useful for the clinical investigation of patients with osteoporosis...
  51. doi request reprint Cortical and trabecular bone distribution in the femoral neck in osteoporosis and osteoarthritis
    H Blain
    INSERM Unit 831 and Université de Lyon, Lyon, France
    Bone 43:862-8. 2008
    ..Furthermore, the spatial distribution of the trabeculae differs between OP and OA whereas cortical thinning is homogenous...
  52. ncbi request reprint [New treatments in osteoporosis]
    R Chapurlat
    Service de rhumatologie et de pathologie osseuse et Inserm U403, Pavillon F, Hopital Edouard Herriot, 5, place Arsonval, 69437 Lyon 03, France
    Rev Med Interne 25:S573-9. 2004
    ..In the next five years, new SERMs and inhibitors of RANK-ligand might be new treatment options...
  53. doi request reprint Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single-column high performance liquid chromatography
    S Viguet-Carrin
    INSERM Research Unit 831, Claude Bernard University of Lyon, Lyon, France
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1-7. 2009
    ..2 pmol for the pyridimium crosslinks and 0.02 pmol for the pentosidine. The inter- and intra-assay coefficients of variation were as low as 5% and 2%, respectively, for all crosslinks...
  54. ncbi request reprint Biochemical assessment of bone turnover and bone fragility in men
    P Szulc
    INSERM Research Unit 831, University of Lyon, Lyon, France
    Osteoporos Int 18:1451-61. 2007
    ..Osteoporosis in men is less studied than in women. Few data concern biochemical bone turnover markers (BTM) in men and their potential use...
  55. ncbi request reprint Homocysteine and fracture risk in postmenopausal women: the OFELY study
    M A Périer
    INSERM Research Unit 831, Pavillon F, Hopital E Herriot, 69437 Lyon Cedex 03, France
    Osteoporos Int 18:1329-36. 2007
    ..After adjustment for age, there was no significant relation between the plasma level of homocysteine and the subsequent risk of fracture...
  56. ncbi request reprint Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease
    P Chavassieux
    Institut National de la Santé et de la Recherche Médicale Unit 831, Pavillon F, Hopital E Herriot, 69437 Lyon Cedex 08, France
    Endocr Rev 28:151-64. 2007
    ..Observations in patients and in animal models provide insights on the biomechanical consequences of these illnesses and the nature of the qualities of bone that determine its strength...
  57. ncbi request reprint Bone width is correlated positively with the upper to the lower segment ratio in elderly men--the MINOS study
    P Szulc
    INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69437 Lyon, France
    Bone 40:194-9. 2007
    ..Given methodological limitations, these results need to be confirmed in a younger and more representative group of men...
  58. ncbi request reprint Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study
    P Chavassieux
    , , Lyon, France
    Osteoporos Int 3:97-102. 1993
    ..The bone formation rate (BFR/B.Pm) also decreased by 84% and the adjusted apposition rate (Aj.AR) by 80%. The increase in the total formation period was mainly due to an increase in the inactive period.(ABSTRACT TRUNCATED AT 250 WORDS)..
  59. ncbi request reprint Biochemical markers of bone turnover in men
    P Szulc
    INSERM Research Unit 403, Claude Bernard University, Lyon, France
    Calcif Tissue Int 69:229-34. 2001
    ..Thus, antiresorptive therapy may be of interest in the prevention and treatment of osteoporosis in men. Further studies are necessary to determine if bone resorption markers predict the risk of fragility fractures in elderly men...
  60. ncbi request reprint Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. European Prospective Osteoporosis Study
    P Vergnaud
    U INSERM 403, Lyon, France
    Clin Chim Acta 322:121-32. 2002
    ..6 - 12-fold even after adjusting for BMD. We examined the possibility that biochemical marker levels were associated with this unexplained BMD-independent element of fracture risk...
  61. ncbi request reprint Expression of Semaphorin-3A and its receptors in endochondral ossification: potential role in skeletal development and innervation
    C Gomez
    INSERM, Unit 403, Lyon, France
    Dev Dyn 234:393-403. 2005
    ..Expression patterns suggest Plexin-A3/Neuropilin-1 as a candidate receptor in target cells for the regulation of bone innervation by Semaphorin-3A...
  62. ncbi request reprint Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial
    P D Delmas
    University Claude Bernard of Lyon, and INSERM Research Unit 403, Hopital Edouard Herriot, Lyon, France
    Bone 33:522-32. 2003
    ..These fractures may reflect architectural deterioration, independent of BMD, leading to increased skeletal fragility...
  63. pmc Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis
    P Garnero
    INSERM Research Unit 403, Lyon, France
    Ann Rheum Dis 62:939-43. 2003
    ..To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA...
  64. doi request reprint Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis
    H Marotte
    Hospices Civils de Lyon bioMérieux Research Unit on Rheumatoid Arthritis, Hospital Edouard Herriot, Lyon, France
    Ann Rheum Dis 68:1197-200. 2009
    ....
  65. ncbi request reprint Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women
    P Garnero
    INSERM Research Unit 403 and Synarc, Lyon, France
    J Musculoskelet Neuronal Interact 4:50-63. 2004
    ..Further studies in osteoporosis should explore the changes in these biochemical parameters of bone matrix as they may represent a key component of bone quality...
  66. ncbi request reprint Beyond hip: importance of other nonspinal fractures
    P D Delmas
    INSERM Research Unit 403 and Université Claude Bernard Lyon 1, Lyon, France
    Am J Med 120:381-7. 2007
    ..It is the clinician's responsibility to attend to and recognize that nonspinal, nonhip fractures are usually associated with osteoporosis and should be treated...
  67. doi request reprint Bone microdamage: a clinical perspective
    R D Chapurlat
    INSERM Research Unit 831, Universite de Lyon, Hopital E Herriot, Hospices Civils de Lyon, 69437 Lyon Cedex 03, France
    Osteoporos Int 20:1299-308. 2009
    ..Microdamage accumulation due to fatigue loading may lead to fracture. In addition, several studies using animal models have suggested in recent years that bisphosphonates might increase microdamage accumulation...
  68. ncbi request reprint Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses
    P D Delmas
    INSERM Research Unit 403, Claude Bernard University of Lyon, Lyon, France
    J Bone Miner Res 19:330-7. 2004
    ..Many factors may affect the outcome of such analyses. Our work explores some of these factors and illustrates the need for caution in interpreting the results of meta-analyses...
  69. ncbi request reprint Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain
    B Merle
    INSERM Research Unit 403, Pavillon F, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    J Cell Biochem 75:538-46. 1999
    ..dermatan-sulfate chains), and is independent of a steric hindrance effect exerted by its glycosaminoglycan side chains...
  70. ncbi request reprint Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial
    P J Meunier
    Hopital Edouard Herriot, 69437 Lyon, France
    J Clin Endocrinol Metab 87:2060-6. 2002
    ..All tested doses were well tolerated; the 2 g/d dose was considered to offer the best combination of efficacy and safety. In conclusion, SR therapy increased vertebral BMD and reduced the incidence of vertebral fractures...
  71. ncbi request reprint Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts
    C Maillard
    INSERM U 234, Hopital Edouard Herriot, Lyon, France
    Endocrinology 130:1599-604. 1992
    ..This finding raises the intriguing possibility that protein-S might play a role in bone turnover and bone mass...
  72. ncbi request reprint Complex formation of human thrombospondin with osteonectin
    P Clezardin
    Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine Alexis Carrel, Lyon, France
    Eur J Biochem 175:275-84. 1988
    ....
  73. ncbi request reprint Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY study
    P Garnero
    INSERM Research Unit 403, Hopital E Herriot, Lyon, France
    Bone 31:43-50. 2002
    ..Larger long-term studies are necessary to assess adequately the relationships between IL-6 genotype, rate of bone loss, and risk of fracture...
  74. ncbi request reprint Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
    Pierre D Delmas
    INSERM Research Unit 831 and University of Lyon, Lyon, France
    Bone 42:36-42. 2008
    ..This randomized, double-blind, multi-center study was designed to assess the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen...
  75. ncbi request reprint Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure
    Robert R Recker
    School of Medicine, Creighton University, Omaha, Nebraska 68131, USA
    J Bone Miner Res 23:6-16. 2008
    ..Zoledronic acid reduced bone turnover by 63% and preserved bone structure and volume, with evidence of ongoing bone remodeling in 99% of biopsies obtained...
  76. ncbi request reprint Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study
    Roland D Chapurlat
    INSERM Research Unit 831 and Université de Lyon, Lyon, France
    J Bone Miner Res 22:1502-9. 2007
    ..We sought whether microdamage could rise in postmenopausal osteoporotic women on long-term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover...
  77. ncbi request reprint Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study
    Ronald Emkey
    Radiant Research, Wyomissing, Pennsylvania 19610, USA
    Arthritis Rheum 48:1102-8. 2003
    ..To evaluate the effects of discontinuing or continuing alendronate (ALN) therapy on bone mineral density (BMD) after patients on a long-term regimen of glucocorticoids (GCs) completed a 1-year treatment period with ALN...
  78. ncbi request reprint Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis
    Aurelie Fontana
    Hopital Edouard Herriot, Place d Arsonval, Pavilion F, 69437 Lyon, Cedex 03, France
    Endocrinol Metab Clin North Am 32:219-32. 2003
    ....
  79. ncbi request reprint Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study
    Elisabeth Sornay-Rendu
    INSERM Research Unit 403, Pavillon F, E Herriot Hospital, 69437 Lyon Cedex 03, France
    Bone 33:159-66. 2003
    ....
  80. ncbi request reprint Biological markers in osteoarthritis
    Jean Charles Rousseau
    INSERM Research Unit on the Pathophysiology of Osteoporosis, Lyon, France
    Nat Clin Pract Rheumatol 3:346-56. 2007
    ..In this Review, we will use the recently proposed BIPED (i.e. burden of disease, investigative, prognostic, efficacy of intervention and diagnostic) classification of OA markers to describe the potential usage of a given marker...
  81. ncbi request reprint Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Dennis M Black
    University of California, San Francisco, San Francisco, CA 94107, USA
    N Engl J Med 356:1809-22. 2007
    ..We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period...
  82. ncbi request reprint Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate
    Monique E Arlot
    INSERM, Universite Lyon 1, Lyon, France
    J Bone Miner Res 23:215-22. 2008
    ..Hence, these effects may explain the decreased fracture rate...
  83. ncbi request reprint Review of ibandronate in the treatment of osteoporosis
    Roland D Chapurlat
    Department of Rheumatology and Bone Diseases, Hôpital E Herriot and Claude Bernard University of Lyon, 5 Place d Arsonval, France
    Expert Opin Pharmacother 4:391-6. 2003
    ..v. every 3 months. Thus, ibandronate can be considered as a promising new option for the treatment of postmenopausal osteoporotic women...
  84. ncbi request reprint NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women
    Pierre D Delmas
    INSERM Research Unit 831 and University of Lyon, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    Bone 42:16-8. 2008
  85. ncbi request reprint Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
    Hans D Menssen
    Department of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universität, and St Hedwigs Krankenhaus, Berlin, Germany
    J Clin Oncol 20:2353-9. 2002
    ..This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients...
  86. ncbi request reprint Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study
    Patrick Garnero
    INSERM Unit 403, Hĵpital E Herriot, Lyon, France
    J Bone Miner Res 17:826-33. 2002
    ..This suggests that alterations of type I collagen isomerization/racemization that can be detected by changes in urinary CTX ratios may be associated with increased skeletal fragility...
  87. pmc The effects of tibolone in older postmenopausal women
    Steven R Cummings
    San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
    N Engl J Med 359:697-708. 2008
    ..Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain...
  88. ncbi request reprint Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial
    Jean Yves Reginster
    University of Liege, Liege, Belgium
    Arthritis Rheum 58:1687-95. 2008
    ..This study was undertaken to assess the effect of strontium ranelate on nonvertebral and vertebral fractures in postmenopausal women with osteoporosis in a 5-year, double-blind, placebo-controlled trial...
  89. doi request reprint Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases
    Pierre D Delmas
    Université de Lyon and INSERM Research Unit 831, Lyon, France
    J Clin Densitom 11:325-38. 2008
    ..The results of these human trials will also be discussed...
  90. ncbi request reprint Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study
    John A Eisman
    Garvan Institute of Medical Research, St Vincent s Campus and University of New South Wales, Sydney, Australia
    J Rheumatol 35:488-97. 2008
    ..We report the effects on lumbar spine and proximal femur bone mineral density (BMD) and bone resorption markers over 2 years...
  91. ncbi request reprint Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men--the MINOS study
    Pawel Szulc
    INSERM Unit 403, Lyon, France
    J Bone Miner Res 20:721-9. 2005
    ....
  92. doi request reprint Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis
    Alan L Burshell
    Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Curr Med Res Opin 24:807-13. 2008
    ..To evaluate the relationship between bone mass and risk of breast cancer and to determine the effect of raloxifene therapy on breast cancer incidence in women categorized by bone mass into low bone mass and osteoporosis subgroups...
  93. ncbi request reprint [Osteoporosis in the aged male]
    Pawel Szulc
    Unité INSERM 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69437 Lyon
    Presse Med 31:1760-9. 2002
    ..In a randomised study, alendronate increased BMD and reduced the incidence of vertebral fractures. Alendronate and risedronate were also effective in the prevention and treatment of cortisone-induced osteoporosis in men...
  94. ncbi request reprint [Advances in the field of osteoporosis]
    Emmanuelle Vignot
    Service de Rhumatologie et de Pathologie Osseuse, Hôpital Edouard Heriot, Unite INSERM, Universite de Lyon
    Rev Prat 57:1629-31. 2007
  95. ncbi request reprint Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
    J Bone Miner Res 23:525-35. 2008
    ..Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD...
  96. pmc Recognizing and reporting osteoporotic vertebral fractures
    Mikayel Grigoryan
    Osteoporosis and Arthritis Research Group, Department of Radiology, University of California San Francisco, 350 Parnassus Avenue, 94117, San Francisco, CA, USA
    Eur Spine J 12:S104-12. 2003
    ....
  97. ncbi request reprint Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis
    Pierre D Delmas
    Institut National de la Santé et de la Recherche Médicale Research Unit 403 and University Claude Bernard, Hopital Edouard Herriot, Pavillon F, 69437 Lyon Cedex 03, France
    J Clin Endocrinol Metab 92:1296-304. 2007
    ..Persistence with osteoporosis treatment is poor but is important for maximum benefit...
  98. ncbi request reprint The fracture risk index and bone mineral density as predictors of vertebral structural failure
    Yunbo Duan
    Department of Endocrinology, Austin Health, The University of Melbourne, 3084, Melbourne, Australia
    Osteoporos Int 17:54-60. 2006
    ..The FRI may not predict incident vertebral fractures...
  99. ncbi request reprint Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, Colorado, USA
    J Bone Miner Res 20:1315-22. 2005
    ..5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year...
  100. ncbi request reprint Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers
    Patrick Garnero
    INSERM Research Unit 403, Lyon, France
    Curr Opin Rheumatol 16:428-34. 2004
    ..More specific biologic markers reflecting systemic quantitative and dynamic changes of bone turnover represent promising adjunctive tools...
  101. ncbi request reprint A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, CHU Centre Ville, Liege, Belgium
    Osteoporos Int 17:159-66. 2006
    ..Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO...